Stockscreener 앱 받기
3.15
4.26%
-0.14
시간 외 거래:
3.15
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy - Benzinga
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy - Yahoo Finance
Mental Disorder Treatment Market Expected to Expand at a Steady - openPR
Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth - Yahoo Finance
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below Fifty Day Moving Average of $3.52 - MarketBeat
Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Below 50 Day Moving Average of $3.52 - Defense World
Mental Disorder Treatment Market Detailed In New Research - openPR
Vistagen shareholders approve board nominees and executive pay By Investing.com - Investing.com Canada
Vistagen shareholders approve board nominees and executive pay - Investing.com
Vistagen shareholders approve board nominees and executive pay By Investing.com - Investing.com UK
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving Average of $3.49 - Defense World
Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above 50 Day Moving Average of $3.49 - MarketBeat
The Globe and Mail - The Globe and Mail
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates - MSN
VTGN (Vistagen Therapeutics) 3-Year Revenue Growth Rate : -47.50% (As of Jun. 2024) - GuruFocus.com
VTGN (Vistagen Therapeutics) Enterprise Value : $-17.63 Mil (As of Aug. 19, 2024) - GuruFocus.com
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) to Post Q2 2025 Earnings of ($0.39) Per Share, William Blair Forecasts - Defense World
VTGN (Vistagen Therapeutics) Cash-to-Debt : 54.45 (As of Jun. 2024) - GuruFocus.com
Q2 2025 EPS Estimates for Vistagen Therapeutics, Inc. Lifted by Analyst (NASDAQ:VTGN) - MarketBeat
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2025 Earnings Call Transcript - Insider Monkey
Vanguard Group Inc. Sells 41,346 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Earnings call: Vistagen advances in Phase 3 trials for SAD treatment - Investing.com Canada
Earnings call: Vistagen advances in Phase 3 trials for SAD treatment - Investing.com
Earnings call: Vistagen advances in Phase 3 trials for SAD treatment - Investing.com UK
VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q1 2025 - InvestorPlace
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update - wallstreet:online
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update - Yahoo Finance
Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday - Defense World
Vistagen Therapeutics (VTGN) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Vistagen Therapeutics (NASDAQ:VTGN) Stock Crosses Below 50-Day Moving Average of $3.60 - MarketBeat
Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024 - businesswire.com
Glutamate Antagonist Market Booming Worldwide With Leading Key Players -Artemis Neuroscience, VistaGen Therapeutics, Rot – Moose Gazette - Moose Gazette
Acadian Asset Management LLC Purchases New Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
3 Stocks Under $15 That Could Make You a Millionaire - Yahoo Finance
Blair William & Co. IL Lowers Stock Position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
3 Stocks Under $15 That Could Make You a Millionaire - InvestorPlace
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving Average of $3.79 - Defense World
Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above 50-Day Moving Average of $3.79 - MarketBeat
Vistagen Therapeutics appoints KPMG as new auditor - Investing.com India
Vistagen Therapeutics appoints KPMG as new auditor By Investing.com - Investing.com Nigeria
Palantir director Alexander Moore sells over $1m in company stock By Investing.com - Investing.com
Vistagen Therapeutics appoints KPMG as new auditor By Investing.com - Investing.com UK
Vistagen Therapeutics appoints KPMG as new auditor - Investing.com
Vistagen secures new patents for PH80 migraine treatment - Pharmaceutical Technology
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine - Business Wire
Key Players and Trends in the Mental Disorder Treatment Market - openPR
Key Players and Trends in the Mental Disorder Treatment Market Scope 2024- 2031 Business Overview, Leading ... - openPR
Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second ... - Yahoo Finance
VistaGen & EverInsight Enter Strategic Collaboration To Develop And Commercialize PH94B - Reuters
Mental Disorder Treatment Market Will Show the Highest Growth Rates and Incredible Demand By 2031 | VistaGen ... - openPR
Gaining Ground: Vistagen Therapeutics Inc. (VTGN) Closes Lower at 3.31, Down -3.22 – DWinneX - The Dwinnex
Earnings Beat: VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Just Beat Analyst Forecasts, And Analysts Have Been ... - Yahoo Movies UK
Vistagen Therapeutics Full Year 2024 Earnings: EPS Beats Expectations - Simply Wall St
Vistagen Therapeutics Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Equities Analysts Offer Predictions for Vistagen Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:VTGN) - Defense World
Q1 2025 EPS Estimates for Vistagen Therapeutics, Inc. Lowered by Analyst (NASDAQ:VTGN) - MarketBeat
2000000 Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Bought by BVF Inc. IL - Defense World
2,000,000 Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Bought by BVF Inc. IL - MarketBeat
1.10%
1.27%
자본화:
|
볼륨(24시간):